

# Nakhle S Saba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8715681/publications.pdf>

Version: 2024-02-01

67  
papers

1,902  
citations

471061

17  
h-index

264894

42  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3192  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 169-176.	5.1	344
2	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2014, 74, 2520-2532.	0.4	207
3	A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. <i>Science Advances</i> , 2021, 7, .	4.7	175
4	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. <i>Blood</i> , 2018, 131, 2357-2366.	0.6	166
5	Pathogenic role of B-cell receptor signaling and canonical NF- $\kappa$ B activation in mantle cell lymphoma. <i>Blood</i> , 2016, 128, 82-92.	0.6	141
6	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2015, 100, 1571-1578.	1.7	137
7	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. <i>Leukemia</i> , 2017, 31, 1340-1347.	3.3	103
8	Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. <i>Nature Nanotechnology</i> , 2021, 16, 1039-1044.	15.6	90
9	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018, 132, 521-532.	0.6	81
10	Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2016, 152, 698.	2.0	42
11	Bortezomib in Plasmablastic Lymphoma: A Case Report and Review of the Literature. <i>Onkologie</i> , 2013, 36, 287-291.	1.1	41
12	MALT1 Inhibition Is Efficacious in Both Na $\kappa$ ve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2017, 77, 7038-7048.	0.4	41
13	Cancer and COVID-19: analysis of patient outcomes. <i>Future Oncology</i> , 2021, 17, 3499-3510.	1.1	28
14	COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2354-2356.	1.3	27
15	The utility of hyperbaric oxygen therapy in post-transplant cyclophosphamide-induced hemorrhagic cystitis: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 1.	0.4	23
16	Adalimumab-Induced Acute Myelogenous Leukemia. <i>Southern Medical Journal</i> , 2008, 101, 1261-1262.	0.3	21
17	Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	21
18	Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs. <i>PLoS ONE</i> , 2013, 8, e75252.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-Induced Hyperpigmentation of the Tongue. <i>New England Journal of Medicine</i> , 2011, 365, e20.	13.9	17
20	Do mantle cell lymphomas have an "Achilles heel"? <i>Current Opinion in Hematology</i> , 2014, 21, 350-357.	1.2	17
21	Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.. <i>Blood</i> , 2012, 120, 2899-2899.	0.6	16
22	Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. <i>Transfusion Medicine</i> , 2021, 31, 217-220.	0.5	15
23	Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 147-147.	0.6	12
24	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
25	Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation. <i>Blood</i> , 2012, 120, 1789-1789.	0.6	10
26	Disruption of pre-B-cell receptor signaling jams the WNT/ $\beta$ -catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. <i>Leukemia Research</i> , 2015, 39, 1220-1228.	0.4	9
27	Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C? inhibitor. <i>Leukemia and Lymphoma</i> , 2011, 52, 877-886.	0.6	8
28	Protein Kinase C-Beta Inhibition Induces Apoptosis and Inhibits Cell Cycle Progression in Acquired Immunodeficiency Syndrome-Related Non-Hodgkin Lymphoma Cells. <i>Journal of Investigative Medicine</i> , 2012, 60, 29-38.	0.7	8
29	Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e105-e112.	0.2	8
30	Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 3819-3819.	0.6	8
31	High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. <i>Leukemia Research</i> , 2021, 106, 106582.	0.4	6
32	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021, 16, 761-771.	1.7	5
33	Quantitative assessment of chromosome instability induced through chemical disruption of mitotic progression. <i>Cell Cycle</i> , 2016, 15, 1706-1714.	1.3	4
34	Successful treatment of "accelerated" chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.. <i>Leukemia Research Reports</i> , 2021, 15, 100247.	0.2	4
35	Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. <i>Leukemia Research</i> , 2021, 101, 106514.	0.4	4
36	Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen. <i>Leukemia Research</i> , 2021, 106, 106583.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning. <i>European Journal of Haematology</i> , 2017, 99, 56-59.	1.1	3
38	The prognostic implications of tetraploidy/near-Tetraploidy in acute myeloid leukemia: a case series and systematic review of the literature. <i>Leukemia and Lymphoma</i> , 2021, 62, 203-210.	0.6	3
39	A Systemic Review of CD5-Negative Mantle Cell Lymphoma Identifies Potential Clinical and Biological Implications. <i>Blood</i> , 2016, 128, 3048-3048.	0.6	3
40	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	0.6	3
41	Cancer of the Indiana Pouch: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e30-e34.	0.9	2
42	Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). <i>Leukemia and Lymphoma</i> , 2021, 62, 2539-2542.	0.6	2
43	Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NF- $\kappa$ B Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma. <i>Blood</i> , 2013, 122, 82-82.	0.6	2
44	CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage. <i>Leukemia and Lymphoma</i> , 2022, 63, 911-917.	0.6	2
45	Adjuvant High-Dose Interferon- $\alpha$ for Resected Melanoma in a Patient with HIV Infection. <i>Oncologist</i> , 2010, 15, 695-698.	1.9	1
46	Neutrophil numerals. <i>Blood</i> , 2014, 123, 1635-1635.	0.6	1
47	Reduction in Cell Viability and in Homeobox Protein Levels Following in Vitro Exposure to $\alpha$ -tocopherol in Acute Myeloid Leukemia. <i>Nutrition and Cancer</i> , 2016, 68, 530-534.	0.9	1
48	A centrocyte blood count of a quarter million. <i>American Journal of Hematology</i> , 2017, 92, 972-973.	2.0	1
49	Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell Lymphoma: A multi-institution retrospective analysis and systematic review. <i>Leukemia Research Reports</i> , 2021, 16, 100263.	0.2	1
50	COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients. <i>Blood</i> , 2020, 136, 40-41.	0.6	1
51	A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1418-1418.	0.6	1
52	COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality. <i>Blood</i> , 2020, 136, 6-7.	0.6	1
53	CRISPR-based Assay Reveals SARS-CoV-2 RNA Dynamic Changes and Redistribution Patterns in Non-Human Primate Model. <i>Emerging Microbes and Infections</i> , 2022, , 1-24.	3.0	1
54	Vitamin E Isoforms Inhibit Cell Proliferation and Downregulate Homeobox Protein Expression in the Leukemic KG-1 Cells. <i>Blood</i> , 2007, 110, 4304-4304.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Selective Protein Kinase C $\hat{I}^2$ Inhibition Induces Apoptosis and Arrests Cell Cycle in AIDS-Related Non-Hodgkin Lymphoma Cell Lines.. Blood, 2009, 114, 4807-4807.	0.6	0
56	Effect of Protein Kinase C $\hat{I}^2$ Specific Inhibition On Acute Lymphoblastic Leukemia Cell Lines.. Blood, 2009, 114, 4817-4817.	0.6	0
57	Enzastaurin Induces Apoptosis and Cell Cycle Arrest in B-Cell Acute Lymphoblastic Leukemia Cell Lines Through AKT Pathway Inhibition and $\hat{A}^{\text{Y}}$ -Catenin Accumulation. Blood, 2012, 120, 1350-1350.	0.6	0
58	The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment. Blood, 2012, 120, 865-865.	0.6	0
59	Direct in Vivo Evidence of Increased Chronic Lymphocytic Leukemia Cell Proliferation in Lymph Nodes Compared to Bone Marrow and Peripheral Blood. Blood, 2012, 120, 184-184.	0.6	0
60	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. Blood, 2013, 122, 3760-3760.	0.6	0
61	Ongoing Activation of the BCR, NF $\hat{I}^{\text{B}}$ , and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironment. Blood, 2014, 124, 2991-2991.	0.6	0
62	Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 487-487.	0.6	0
63	Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF- $\hat{I}^{\text{B}}$ Pathway in Chronic Lymphocytic Leukemia Primary Cells. Blood, 2016, 128, 1597-1597.	0.6	0
64	Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma. Blood, 2016, 128, 4644-4644.	0.6	0
65	The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1288-1288.	0.6	0
66	Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 2908-2908.	0.6	0
67	Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351. Blood, 2020, 136, 19-19.	0.6	0